Partial compliance with antipsychotics and its impact on patient outcomes

Meera Narasimhan; Chi Un Pae; Natasha Masand; Prakash Masand

doi:10.1080/13651500600973568

Partial compliance with antipsychotics and its impact on patient outcomes

Meera Narasimhan
, Chi Un Pae
, Natasha Masand
, Prakash Masand

Department of Psychiatry

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

Partial compliance with antipsychotic medications is a common and complex phenomenon that is underestimated by physicians. The consequences of partial compliance include an increased risk of relapse, rehospitalization and suicide attempts. Stigma, negative attitudes towards medications, cognitive impairment and diminished insight negatively impact treatment adherence. Oral atypical antipsychotics may improve both insight and cognitive function, but compliance with these agents is not assured. Depot conventional antipsychotics ensure medication delivery but are associated with side-effects such as EPS and dysphoria that decrease compliance. Long-acting atypicals provide significant symptom improvement, foster adherence and may help achieve improvement in insight and cognition. Addressing issues of partial and non-compliance is a significant consideration in relapse prevention strategies for patients with schizophrenia, given the devastating consequences associated with psychotic relapses.

Original language	English
Pages (from-to)	102-111
Number of pages	10
Journal	International Journal of Psychiatry in Clinical Practice
Volume	11
Issue number	2
DOIs	https://doi.org/10.1080/13651500600973568
State	Published - 2007

Bibliographical note

Funding Information:
Meera Narasimhan: Grant and Research support: AstraZeneca, Bristol-Myers Squibb Company, Jans-sen Pharmaceutica; Consultant/ Speaker’s Bureau: Bristol-Myers Squibb Company, Janssen Pharma-ceutica, Pfizer Inc., AstraZeneca, Bristol-Myers Squibb Company, Abbott Lab Prakash S. Masand: Grant and Research support: AstraZeneca, Bristol-Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Ortho McNeil Pharmaceutical, Inc., Janssen Pharmaceu-tica, Wyeth Pharmaceuticals; Consultant: Bristol-Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Health Care Technology, Janssen Pharmaceutica, Jazz Pharmaceuticals, Organon, Pfizer Inc., Wyeth Pharmaceuticals; Speaker’s Bu- reau: AstraZeneca, Bristol-Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc., Wyeth Pharmaceuticals; Stockholder: psychCME Inc.

Keywords

Adherence
Antipsychotic
Partial compliance
Psychosis
Schizophrenia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/13651500600973568

Cite this

@article{b0555cfe7c7d4e46971783ac9f158ba6,

title = "Partial compliance with antipsychotics and its impact on patient outcomes",

abstract = "Partial compliance with antipsychotic medications is a common and complex phenomenon that is underestimated by physicians. The consequences of partial compliance include an increased risk of relapse, rehospitalization and suicide attempts. Stigma, negative attitudes towards medications, cognitive impairment and diminished insight negatively impact treatment adherence. Oral atypical antipsychotics may improve both insight and cognitive function, but compliance with these agents is not assured. Depot conventional antipsychotics ensure medication delivery but are associated with side-effects such as EPS and dysphoria that decrease compliance. Long-acting atypicals provide significant symptom improvement, foster adherence and may help achieve improvement in insight and cognition. Addressing issues of partial and non-compliance is a significant consideration in relapse prevention strategies for patients with schizophrenia, given the devastating consequences associated with psychotic relapses.",

keywords = "Adherence, Antipsychotic, Partial compliance, Psychosis, Schizophrenia",

author = "Meera Narasimhan and Pae, \{Chi Un\} and Natasha Masand and Prakash Masand",

note = "Funding Information: Meera Narasimhan: Grant and Research support: AstraZeneca, Bristol-Myers Squibb Company, Jans-sen Pharmaceutica; Consultant/ Speaker{\textquoteright}s Bureau: Bristol-Myers Squibb Company, Janssen Pharma-ceutica, Pfizer Inc., AstraZeneca, Bristol-Myers Squibb Company, Abbott Lab Prakash S. Masand: Grant and Research support: AstraZeneca, Bristol-Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Ortho McNeil Pharmaceutical, Inc., Janssen Pharmaceu-tica, Wyeth Pharmaceuticals; Consultant: Bristol-Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Health Care Technology, Janssen Pharmaceutica, Jazz Pharmaceuticals, Organon, Pfizer Inc., Wyeth Pharmaceuticals; Speaker{\textquoteright}s Bu- reau: AstraZeneca, Bristol-Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc., Wyeth Pharmaceuticals; Stockholder: psychCME Inc.",

year = "2007",

doi = "10.1080/13651500600973568",

language = "English",

volume = "11",

pages = "102--111",

journal = "International Journal of Psychiatry in Clinical Practice",

issn = "1365-1501",

publisher = "Taylor and Francis Ltd.",

number = "2",

}

TY - JOUR

T1 - Partial compliance with antipsychotics and its impact on patient outcomes

AU - Narasimhan, Meera

AU - Pae, Chi Un

AU - Masand, Natasha

AU - Masand, Prakash

N1 - Funding Information: Meera Narasimhan: Grant and Research support: AstraZeneca, Bristol-Myers Squibb Company, Jans-sen Pharmaceutica; Consultant/ Speaker’s Bureau: Bristol-Myers Squibb Company, Janssen Pharma-ceutica, Pfizer Inc., AstraZeneca, Bristol-Myers Squibb Company, Abbott Lab Prakash S. Masand: Grant and Research support: AstraZeneca, Bristol-Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Ortho McNeil Pharmaceutical, Inc., Janssen Pharmaceu-tica, Wyeth Pharmaceuticals; Consultant: Bristol-Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Health Care Technology, Janssen Pharmaceutica, Jazz Pharmaceuticals, Organon, Pfizer Inc., Wyeth Pharmaceuticals; Speaker’s Bu- reau: AstraZeneca, Bristol-Myers Squibb Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc., Wyeth Pharmaceuticals; Stockholder: psychCME Inc.

PY - 2007

Y1 - 2007

N2 - Partial compliance with antipsychotic medications is a common and complex phenomenon that is underestimated by physicians. The consequences of partial compliance include an increased risk of relapse, rehospitalization and suicide attempts. Stigma, negative attitudes towards medications, cognitive impairment and diminished insight negatively impact treatment adherence. Oral atypical antipsychotics may improve both insight and cognitive function, but compliance with these agents is not assured. Depot conventional antipsychotics ensure medication delivery but are associated with side-effects such as EPS and dysphoria that decrease compliance. Long-acting atypicals provide significant symptom improvement, foster adherence and may help achieve improvement in insight and cognition. Addressing issues of partial and non-compliance is a significant consideration in relapse prevention strategies for patients with schizophrenia, given the devastating consequences associated with psychotic relapses.

AB - Partial compliance with antipsychotic medications is a common and complex phenomenon that is underestimated by physicians. The consequences of partial compliance include an increased risk of relapse, rehospitalization and suicide attempts. Stigma, negative attitudes towards medications, cognitive impairment and diminished insight negatively impact treatment adherence. Oral atypical antipsychotics may improve both insight and cognitive function, but compliance with these agents is not assured. Depot conventional antipsychotics ensure medication delivery but are associated with side-effects such as EPS and dysphoria that decrease compliance. Long-acting atypicals provide significant symptom improvement, foster adherence and may help achieve improvement in insight and cognition. Addressing issues of partial and non-compliance is a significant consideration in relapse prevention strategies for patients with schizophrenia, given the devastating consequences associated with psychotic relapses.

KW - Adherence

KW - Antipsychotic

KW - Partial compliance

KW - Psychosis

KW - Schizophrenia

UR - https://www.scopus.com/pages/publications/34248574727

U2 - 10.1080/13651500600973568

DO - 10.1080/13651500600973568

M3 - Review article

AN - SCOPUS:34248574727

SN - 1365-1501

VL - 11

SP - 102

EP - 111

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

IS - 2

ER -

Partial compliance with antipsychotics and its impact on patient outcomes

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this